JAN (NYSE:JAN) Upgraded at Zacks Research

Zacks Research upgraded shares of JAN (NYSE:JAN) to a hold rating in a research report sent to investors on Wednesday,Zacks.com reports.

A number of other equities analysts have also recently issued reports on JAN. Scotiabank assumed coverage on shares of JAN in a research report on Tuesday. They set a “sector outperform” rating and a $28.00 price objective on the stock. Morgan Stanley started coverage on JAN in a research report on Tuesday. They issued an “overweight” rating and a $28.00 target price for the company. Wall Street Zen raised JAN to a “hold” rating in a research note on Saturday, April 4th. Wells Fargo & Company began coverage on JAN in a research note on Tuesday. They issued an “overweight” rating and a $27.00 price objective for the company. Finally, Barclays initiated coverage on JAN in a report on Tuesday. They set an “overweight” rating and a $26.00 price objective for the company. Ten research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $27.27.

JAN Stock Down 0.3%

NYSE:JAN opened at $25.80 on Wednesday. The firm has a market capitalization of $6.63 billion, a price-to-earnings ratio of -62.29 and a beta of 2.16. JAN has a 12 month low of $22.76 and a 12 month high of $26.70.

Insider Activity

In other JAN news, Director Katherine M. Sandstrom bought 13,500 shares of the firm’s stock in a transaction dated Monday, March 23rd. The stock was bought at an average cost of $20.00 per share, with a total value of $270,000.00. Following the completion of the transaction, the director directly owned 21,000 shares in the company, valued at approximately $420,000. The trade was a 180.00% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Also, COO Jeffrey H. Miller bought 7,500 shares of the stock in a transaction that occurred on Monday, March 23rd. The stock was acquired at an average price of $20.00 per share, for a total transaction of $150,000.00. Following the acquisition, the chief operating officer directly owned 7,500 shares in the company, valued at $150,000. The trade was a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last three months, insiders acquired 187,000 shares of company stock valued at $3,740,000. 3.00% of the stock is currently owned by insiders.

Key JAN News

Here are the key news stories impacting JAN this week:

• Positive Sentiment: KeyCorp published detailed EPS estimates and an Overweight rating with a $28 price target, raising near-term EPS expectations for FY2026–FY2027 (KeyCorp model shows FY2027 EPS of ~$1.13). This provides a clear analyst growth baseline that can support the share price. MarketBeat JAN page
• Positive Sentiment: William Blair reaffirmed a Buy on JAN, signaling confidence in the lead asset JANX007 and the company’s PSMA prostate-cancer franchise expansion — a vote of conviction from a specialist oncology analyst. TipRanks article
• Positive Sentiment: Multiple large banks and research shops have started or expanded coverage with constructive stances — including coverage initiations (Scotiabank, JPMorgan, BofA, RBC) and Overweight/Outperform calls from Barclays, Wells Fargo and BNP Paribas Exane — which should increase institutional visibility and trading interest. Coverage initiation example (Scotiabank)
• Neutral Sentiment: Zacks issued an action described as an “upgrade” to Hold — not strongly bullish — so this is more of a sentiment/stability signal than a catalyst. Zacks.com
• Neutral Sentiment: Goldman Sachs is reported as Neutral — a reminder that not all coverage is uniformly bullish and some firms are taking a cautious stance that could cap near-term upside. AmericanBankingNews – Goldman Sachs note

JAN Company Profile

Upon completion of this offering, we will be the only U.S. publicly traded REIT focused exclusively on the senior housing sector and the only U.S. publicly traded REIT whose entire portfolio is owned and operated under RIDEA structures. We have an initial portfolio consisting of 34 senior housing communities, comprised of 10,422 units as of December 31, 2025. Our communities are located primarily in major retirement markets across 10 states, with units in Florida and Texas representing 69% of the total units as of December 31, 2025.